Gil M. Lewitus MSc, PhD

Gil M. Lewitus is a Chief Scientific Officer at the CaVnox. Dr. Lewitus did his graduate studies in neuroimmunology at the Weizmann Institute of Science in Israel, focusing on elucidating the mechanisms underlying T-cell brain maintenance in mental disorders such as post-traumatic stress disorder and schizophrenia. He continues to do a post-doctoral fellowship at the Centre for Research in Neuroscience at McGill University in Montreal where he focused on understanding the role of microglia (the immune cells of the brain) in regulating synaptic plasticity. Specifically, the role of microglial-derived TNF-alpha in regulating medium spiny neuron activity in different striatal dysfunction, such as ALS and drug addiction. Upon completion of his post-doctoral fellowship, he joins the laboratory of associate professor Dedi Meiri and he is the head of the team researching the effects of medical cannabis on the brain. Dr. Lewitus and his team are interested in understanding how the different strains of cannabis and their active components (such as phytocannabinoids and terpenes) can be used as a neuroprotective agent in a variety of neurological disorders ranging from epilepsy, neurodegeneration disease, and sleep.